← All trials
NCT04345276
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2020
- Primary completion
- Apr 30, 2020
- Completion date
- May 31, 2020
- First posted
- Apr 14, 2020
- Last posted
- Apr 14, 2020
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wuhan Huoshenshan HospitalLead sponsor
- Ascletis Pharmaceuticals Co., Ltd.Study director
- Ascletis Pharmaceuticals Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.